Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Drug Pricing Rules to Be Applied to Takeda’s Cell Therapy Alofisel: Chuikyo
October 14, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- Label Revisions Ordered for Ivermectin to Add Disturbed Consciousness to ADR List
October 13, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
- LDP Seeks to Give More Power to Govt in Pandemic Response: Election Platform
October 11, 2021
- Kishida Poised to Revise Law to Boost Command Tower Functions for Emergency Control
October 11, 2021
- Nordic Restriction on Moderna Jab Won’t Affect Japan Inoculation Program: Minister
October 11, 2021
- Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
- Senior Vice Minister Yamamoto, Parliamentary Secretary Shimamura Responsible for Healthcare
October 8, 2021
- MHLW Publishes Application Statuses for Infertility Treatments
October 7, 2021
- Atsushi Koga, Hiroshi Yamamoto Named Senior Vice Health Ministers
October 7, 2021
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- Innovative Drug Makers Log Sluggish Generic Use Rates: MHLW Data
October 5, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…